Industry news round-up: updates from August 2024
Discover the latest industry developments in real-world data (RWD) and real-world evidence (RWE) as reported in The Evidence Base from August 2024 in our regular monthly column.
Verana Health and HealthVerity partner to enhance clinical insights with real-world evidence
Verana Health and HealthVerity will work together to integrate registry RWD, enhancing clinical research and patient care in ophthalmology, urology and neurology.
Lynx.MD and Schweiger Dermatology Group partnered to create a RWD repository to enhance dermatology research and patient care, leveraging extensive patient data.
Updated report summarizes EMA’s progress in utilizing real-world data for EU regulations
The European Medicines Agency’s latest report highlights progress in using RWD for EU regulations, noting 41 studies, expanded data partners, and advancements in integrating RWE into regulatory decisions.
New real-world study unveils key trends in GLP-1 RA discontinuation and reinitiation
A recent study by Truveta Research, in collaboration with Dr Ezekiel Emanuel from the University of Pennsylvania Perelman School of Medicine, uncovered insights into the patterns of discontinuation and reinitiation of GLP-1 receptor agonists.
Canada’s Drug Agency aims to enhance drug evaluation by integrating RWE, focusing on data sharing, transparency, and collaboration to refine post-market assessments.
The study of nearly 46 million adults in England published in Nature Communications sheds light on the cardiovascular safety of different vaccination doses, and supports the continued use of COVID-19 vaccines as a critical component of public health strategies.
NICE releases guidance on integrating AI into real-world evidence generation
NICE has released guidance for use of AI in RWE generation, emphasizing transparency, rigorous validation and human oversight to ensure ethical, accurate health technology assessments.
NICE draft guidance opposes NHS coverage for the Alzheimer’s drug lecanemab
The MHRA has approved lecanemab for early-stage Alzheimer’s, but NICE’s draft recommendation blocks NHS access.
OMNY Health expands real-world data ecosystem with new GLP-1 data network
OMNY Health’s new GLP-1 data network enhances clinical research by integrating RWD from the electronic health record data of 645,000 patients, advancing insights into diverse populations and improving healthcare outcomes.
Scottish project leverages AI and real-world data to enhance early dementia diagnosis
The AI initiative utilizes RWD from brain scans to predict dementia risk, aiming to enhance early diagnosis and treatment through the NEURii global research collaboration.
Want regular updates on the latest real-world evidence news straight to your inbox? Become a member on The Evidence Base® today>>>
